Previously, a rat brain cDNA was reported that was designated ␣6 because of its homology with nicotinic acetylcholine receptor (AChR) ␣ subunits, being especially similar to ␣3, but no acetylcholine-gated cation channels were detected when it was expressed in Xenopus laevis oocytes alone or in combination with other known rat AChR subunits. We cloned chicken ␣6 and human ␤4 AChR subunits and tested for acetylcholine-gated cation channels with ␣6 by expression in X. laevis oocytes alone or in pairwise combination with chicken ␣3, ␤2, or ␤4 or with human ␣3, ␤2, or ␤4 AChR subunits. Chicken ␣6 formed detectable functional AChRs only when expressed together with the human ␤4 subunit. The ␣6␤4 AChR-mediated currents show strong inward rectification and dependence on extracellular Ca 2ϩ . It exhibited a distinct pharmacological profile with an EC 50 value of 28 M for acetylcholine, 24 nM for (ϩ)-epibatidine, 6.6 M cytisine, and 15 M 1,1-dimethyl-4-phenylpiperazinium. Both cytisine and 1,1-dimethyl-4-phenylpiperazinium behaved as partial (ϳ30%) agonists. Remarkably, nicotine (EC 50 ϭ 22 M) was an even weaker partial agonist (ϳ18%) and had a relatively long-lasting inhibitory effect. Coexpression of the previously cloned rat ␣6 subunit with the human the ␤4 subunit also resulted in functional ␣6␤4 AChRs with properties resembling those of the chicken/human ␣6␤4 AChRs. Therefore, ␣6 can function as part of AChRs with unusual pharmacological properties.
The family of nicotinic AChRs consists of subunits termed ␣1-␣9, ␤1-␤4, ␥, ␦, and ⑀. All of these subunits, except the "orphans" ␣6 and ␤3, have been shown to function as components of ACh-gated cation channels either as homomers or in combination with one or more other AChR subunits (1) (2) (3) (4) .
Despite the fact that the cDNA sequence of the ␣6 AChR subunits has been known for several years (1) , little data are available regarding the properties of this subunit. These data are limited to mentions in reviews of cDNA sequences of rat and chick subunits (4, 5) , a recently submitted cDNA sequence of the human subunit (6) , and published abstracts concerning ␣6 mRNA distribution in rat brain and cochlea (7, 8) . High levels of sequence homology between ␣6 and ␣3 AChR subunits (Ͼ75%) and other features common to all functional nicotinic subunits (5) indicated that ␣6 subunits should form functional AChRs serving as a ligand-binding subunit. However, difficulties in obtaining functional AChRs formed exclusively or partially by this subunit have suggested that ␣6 may serve a structural role in combination with other ␣ and ␤ subunits as ␣5 does (9, 10) , that it may require the presence of another subunit yet to be identified to function as an AChR, or that ␣6 may function as a receptor for some other ligand yet to be identified.
We show that ␣6 subunits can, in fact, act as ligandbinding subunits in functional AChRs. Here, we report cloning of cDNAs encoding ␣6 AChR subunits from a chicken cochlea library and a ␤4 AChR subunit from a human neuroblastoma SH-SY5Y library. When expressed in Xenopus laevis oocytes together with the human ␤4 subunit, chicken or rat ␣6 AChR subunits form nicotinic ligand-gated cation channels with novel pharmacological properties. Identification of this new subtype of AChR may prove important for understanding the pharmacological properties of centrally acting cholinergic ligands with possible therapeutic significance.
Materials and Methods
Isolation of chicken ␣6 and human ␤4 cDNA clones. A lambda Zap II cDNA library (ϳ9 ϫ 10 6 plaques) using chick cochlear mRNA, constructed by Stratagene (La Jolla, CA), was kindly provided by Dr. Paul Fuchs (Johns Hopkins University, Baltimore, MD). The chicken ␣6 cDNA was obtained by screening ϳ5 ϫ 10 5 plaques from this library at low stringency using previously cloned chick ␣3, ␣4, ␣5, ␣7, ␣8, and ␤2, rat ␣2, ␤3, and ␤4, and human ␣1, ␤1, ␥, and ␦ full-length or nearly full-length cDNA probes. The human ␤4 cDNA clone was obtained by screening a previously described lambda Zap II cDNA library (11) constructed using mRNA isolated from the human neuroblastoma cell line SH-SY5Y with human ␣3, ␣4, ␣5, ␣7, ␤2, and ␤4 and rat ␣2, ␤3, and ␣6 full-length or nearly full-length cDNA probes. All rat AChR subunit cDNAs used were kindly provided by Drs. Stephen Heinemann and Jim Boulter (Salk Institute, San Diego, CA). A human ␣5 cDNA clone and a partial ␤4 cDNA clone were kindly provided by Dr. Francesco Clementi (University Degli Studi di Milano, Milano, Italy). The low-stringency screens were performed by hybridizing the membranes overnight at 42°in 30% formamide, 5 ϫ SSPE (1ϫ ϭ 0.18 M NaCl, 0.01 M sodium phosphate, pH 7.4, 1 mM EDTA), 1% SDS, 5 ϫ Denhardt's solution (1 ϫ Denhardt's ϭ 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 150 mg/ml sonicated salmon sperm DNA. The membranes were washed successively in 5 ϫ SSPE and 0.1% SDS, at room temperature, and in 2 ϫ SSPE and 0.1% SDS at 42°for 30 min each. Autoradiography was performed by exposing the membranes to Kodak XAR-5 film (Eastman Kodak, Rochester, NY) for 1-2 days. Clones thus isolated were purified and subjected to dideoxy sequencing using the Sequenase 2 Kit (United States Biochemical, Cleveland, OH). The identity of each clone was then determined by searching for their sequences against the sequences contained in the National Center for Biotechnology Information database using the Blast suite of programs (12) . Alignment of the peptide sequences was performed using MacVector (Eastman Kodak) and The Wisconsin Package (Genetics Computer Group, Madison, WI).
Other cDNAs. Chicken ␤2 cDNA was described previously (13) . Rat ␣6 was kindly provided by Drs. Stephen Heinemann and Jim Boulter. Human ␣3 was cloned from a human brain library. Chicken ␣3, ␤2, and ␤4 cDNAs were obtained through the generosity of Dr. Marc Ballivet (Department of Biochemistry, University of Geneva, Geneva, Switzerland).
Expression of AChR subunits in X. laevis oocytes. Chicken and human cDNAs were cloned into a modified SP64T expression vector (14) using standard DNA cloning procedures. cRNA was synthesized in vitro using the Megascript kit (Ambion, Austin, TX). Oocytes were defolliculated and injected with either 15 or 100 ng of cRNA per oocyte. Chicken ␣3, ␤2, and ␤4 subunits were expressed by nuclear injections of 2 ng of genomic DNAs per oocyte. The oocytes were incubated in semisterile conditions at 18°in saline solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, pH 7.6) containing 50% Leibovitz-15 media (GIBCO/BRL, Gaithersburg, MD) buffered to pH 7.4 with 10 mM HEPES. Oocytes were incubated at 18°for 3-6 days before use.
Electrophysiological procedures and drug application. Currents in oocytes were measured using a standard two-microelectrode voltage clamp amplifier (oocyte clamp OC-725; Warner Instrument, Hamden, CT). Electrodes were filled with 3 M KCl and had resistances of 0.5-1.0 M⍀ for the voltage electrode and 0.4-0.6 M 1 ⁄2 for the current electrode. All records were digitized (MacLab/2e interface and Scope software; AD Instruments, Castle Hill, Australia), stored on a Macintosh IIcx computer (Apple Computer, Cupertino, CA) and analyzed using AXOGRAPH software (Axon Instruments, Burlingame, CA).
The recording chamber was continually perfused at a flow rate of 10 ml/min with a saline solution containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, pH 7.6. In most experiments, 1 M atropine was added to the solution to suppress endogenous muscarinic responses in X. laevis oocytes. Application of the agonists was performed as described in detail previously (15) . All agonists were applied by means of a set of 2-mm glass tubes directed on the animal pole of the oocyte. Application was achieved by manual unclamping and clamping of a flexible tube connected to the syringe with the test solution. Typical delay between beginning of the application and first deflection of the induced current was approximately 0.3 sec.
The Hill equation was fitted to the concentration-response relationships using a nonlinear least-squares error curve fit method (KaleidaGraph software; Abelbeck/Synergy, Reading, PA):
, where I(x) is current measured at the agonist concentration x, I max is the maximal current response at the saturating agonist concentration, EC 50 is the agonist concentration required for the half-maximal response, and n is the Hill coefficient.
Drugs used. Epibatidine (oxalate salt) was synthesized at Merck Sharp & Dohme Research Laboratories (Essex, UK) and was a gift from Stephen Fletcher (16) . (Ϫ)-Nicotine tartrate, cytisine, DMPP, and ACh chloride were obtained from Sigma (St. Louis, IL).
Results
Isolation and primary structure of the chick ␣6 AChR subunit. A chicken cochlea cDNA library was screened at low-stringency hybridization conditions using a cocktail of AChR subunit cDNA probes. In addition to identifying cDNAs for ␣4, ␣7, ␤2, and ␤4 subunits, one 2233-bp cDNA was identified that closely resembled the previously cloned rat ␣6 AChR subunit (Genbank accession number L08277) as shown in Fig. 1A . The cDNA encodes a predicted mature protein of 464 amino acid residues, preceded by a leader peptide of 30 residues. The sequence contains a cysteine pair homologous to ␣1 128 and 142 and a second cysteine pair homologous to ␣1 192 and 193, which identify it as an ␣ subunit. The sequence also contains the four putative transmembrane sequences typical of all AChR subunits. The predicted amino-acid sequence of mature chicken ␣6 is 86%, identical to that of rat ␣6 and 88% identical to human ␣6 (Fig. 1) . Most sequence differences occur in the putative large cytoplasmic loop between transmembrane domains three and four, which is the region that typically shows the most variation between species of AChR subunits. Chicken and rat ␣6 subunits are identical both in parts of the sequence believed to contribute to the ACh binding site (e.g., amino acids of the mature protein 180-200) and in the lining of the cation channel (i.e., amino acids 200-250); therefore, ␣6 subunits from the two species would be expected to have both similar ligand binding and cation channel characteristics.
Isolation and primary structure of the human ␤4 AChR subunit. The deduced amino acid sequence of the human ␤4 AChR subunit obtained by low-stringency screening of a SH-SY5Y cDNA library is compared with the rat and chicken ␤4 subunits in Fig. 1B . Protein encoded by the human ␤4 cDNA has substantial identity with sequences of the chick (75%) and rat (85%) ␤4 AChRs. A leader peptide, four hydrophobic putative transmembrane domains, and two highly conserved cysteine residues at positions 153 and 167 are characteristic of all ␤-type subunits. Designation of this clone as a ␤ subunit was confirmed by functional tests in which it was shown to form functional AChRs when expressed in combination with human ␣3 subunits (Fig. 2 ). An incomplete, nonfunctional human ␤4 AChR cDNA was published earlier (17) .
Functional expression of the chicken ␣6 AChR subunit. Multiple attempts to detect functional nicotinic AChRs in X. laevis oocytes injected with in vitro synthesized chicken ␣6 transcripts either alone or after prior nuclear injection of molpharm.aspetjournals.org chick ␤2, ␤3, or ␤4 cRNAs were unsuccessful (Fig. 2) . Parallel control experiments with pair-wise coexpression of ␤2 or ␤4 together with ␣3 confirmed the functionality of these cDNAs. Additionally, no functional AChRs were detected when oocytes were injected with mixtures containing 15-100 ng per oocyte of both in vitro synthesized ␣6 and ␤4 transcripts (these were obtained by linearizing the chicken ␣3 cDNA recloned into the NotI site of the pBS SK(Ϫ) vector). Functionality of ␤4 cRNA was confirmed by successful coexpression with the chicken ␣4 AChR subunit. In general, maximal currents resulting from expression of the chicken ␣3␤2 (Fig.  3) , ␣3␤4, and ␣4␤4 subunit combinations in oocytes clamped at Ϫ70 mV did not exceed 500 nA.
We continued to search for ␣6 function by coexpressing this subunit with human ␣3, ␤2, or ␤4 subunits (Fig. 2) . Only oocytes injected with both ␣6 and ␤4 subunits produced detectable responses to ACh. These responses could be detected only more than 72 hr after cRNA injection and only in about 50% of the injected oocytes. Expression typically reached a plateau on day 5 or 6 after cRNA injection. Peak amplitudes of the currents in oocytes clamped at Ϫ100 mV ranged from 5 to 250 nA; most responses were lower than 100 nA. By contrast, currents mediated by human ␣3␤2 and ␣3␤4 AChRs were much larger (3-5 A). ␣6␤4 AChR currents usually did not show significant rundown, even after 2 hr of recording.
Oocytes expressing ␣6␤4 AChRs responded to ACh in a concentration-dependent manner ( Fig. 3 ) with a EC 50 value of 28 M and a Hill coefficient greater than 1. Maximal responses were obtained using 300 M ACh. Further increase of the concentration resulted in decreased peak amplitude. Presence of "rebound" currents after termination of the application of high ACh concentrations (Ͼ100 M) indicated a possible channel block effect of this agonist. At all concentrations, responses exhibited relatively slow activation and desensitization kinetics. ␣6␤4 AChR-mediated responses exhibited a nonlinear voltage dependence typical of neuronal nicotinic AChRs. Currents reversed at Ϫ17 Ϯ 3 mV (n ϭ 5). Strong inward rectification was observed not only at positive potentials but also at negative potentials at which the current/voltage dependence significantly deviated from linearity (Fig. 3) . "Rebound" current upon agonist removal (Fig. 3 ) was attributed to recovery from agonist-mediated channel blockage. It correlated with holding potential, being more prominent at more negative potentials.
Amplitude of the ␣6␤4-mediated currents was dramatically attenuated [to 33 ϩ 5% (n ϭ 5)] upon removal of Ca 2ϩ ions from the external solution (Fig. 3) . Voltage dependence of the resulting responses showed less inward rectification at both positive and negative potentials (Fig. 3) . Reversal potential in low Ca 2ϩ had a tendency to shift to the more positive potentials. More precise estimation of this shift was Fig. 1 . A, amino acid sequence alignment of chicken, rat, and human AChR ␣6 subunits. B, amino acid sequence alignment of the human, rat, and chicken ␤4 AChR subunits. Shading, identical residues. Gaps were introduced in the sequences to maximize homologies. Arrows, positions of the predicted leader peptide, cysteine residues conserved in all AChR subunits; arrowheads, cysteine residues conserved in all ␣ subunits; TMD1-TMD4, putative transmembrane domains. (Fig. 4) . Inhibition by curare showed relatively fast on and off rates. Half-time for inhibition of the response by coapplication of curare with ACh was approximately 2 sec (n ϭ 4), whereas recovery of the ACh response followed the more rapid time course of the solution exchange in the perfusion system used (half-time approximately 0.2 sec). Mecamylamine (10 M; Fig. 4 ) effectively inhibited ␣6␤4 AChR-mediated currents with much slower washout than curare. When either mecamylamine (at 10 M) or hexamethonium (at 30 M) were coapplied with ACh, it took more than 30 sec to reach steady-state inhibition and the response recovered fully only after 8-10 min of washing with test ACh responses every 2 min. No attenuation of the responses was observed after 1-hr incubation in 200 nM ␣-bungarotoxin.
A novel pharmacological profile of ␣6␤4 AChRs was revealed by using various nicotinic agonists. Nicotine seemed to behave as a very poor partial agonist with maximal currents at 18% of the current induced by a saturating concentration of ACh (Fig. 4) . Moreover, at high concentrations (Ͼ100 M), nicotine behaved as a long-lasting antagonist, inhibiting currents induced by subsequent applications of ACh (Fig. 4) . Partial recovery of the response from the inhibition induced by a 4-sec application of nicotine was observed only after 10-15 min. Both cytisine and DMPP also behaved as partial agonists, with 36% and 27% efficacy, respectively, relative to ACh (Fig. 4) . The (ϩ)-enantiomer of the synthetic alkaloid epibatidine behaved as a full agonist and exhibited extremely high potency for ␣6␤4 AChRs with an EC 50 of 24 nM (Fig. 4) . EC 50 values for the agonists tested are listed in Table 1 . The rank order of potency of nicotinic agonists for the activation of the ␣6␤4 AChRs was epibatidineϾ ϾcytisineϾDMPPՆnicotineϾACh.
Functional expression of the rat ␣6 AChR subunit. Coexpression of the rat ␣6 subunit, along with the human ␤4 subunit, resulted in appearance of ACh-induced inward currents that resembled those observed for chick ␣6 human ␤4 AChRs (Fig. 5) , as expected from the sequence identities of ␣6 subunits from the two species in both the regions believed to govern ACh binding and channel function (Fig. 1) . Currents reversed around Ϫ15 mV, and the current/voltage showed strong inward rectification. Rat ␣6 human ␤4 AChR-mediated currents were inhibited by curare (n ϭ 4) (Fig. 5) . ACh was slightly less potent on rat ␣6 AChRs (EC 50 ϭ 37 M) compared with chicken ␣6 AChRs. Nicotine, cytisine, and DMPP behaved as partial agonists with 52%, 30%, and 19% efficacy, respectively, compared with ACh (Fig. 5) .
Discussion
␣6 subunits are most closely related in sequence to ␣3 subunits (ϳ75% amino acid sequence identity) (4, 5) . In contrast to ␣3 subunits, coexpression of the chick ␣6 subunit with either chick or human ␤2 subunits did not yield detectable AChR function. It is not clear whether this is an intrinsic attribute of the ␣6 subunit that discriminates between assembly properties of the ␣3 and ␣6 subunit or if it is due to technical shortcomings. Maximal currents detected for the ␣3␤4 combination were almost two orders of magnitude higher compared with the ␣6␤4 combination. This might indicate that ␣6 and ␣3 subunits differ in assembly affinity for the ␤4 subunit and/or, possibly, additional subunits are required for more effective functional expression of the ␣6 subunit. On the other hand, the relatively small amplitudes of the ␣6␤4-mediated currents and failure to detect function on coexpression with the ␤2 subunit could reflect levels of ␣6 expression insufficient for functional detection. We have no independent measure of the quality of the ␣6 cRNA or the amount of ␣6 protein produced. The low overall levels of ␣6␤4 AChR function detected also may reflect inefficient processing or assembly of ␣6 in X. laevis oocytes compared with the neurons in which ␣6 might normally be found. There is, as yet, no characterization of ␣6 protein or function in neurons with which to compare the properties of these cDNAs expressed in X. laevis oocytes.
Despite the very high level of homology between ␣6 and ␣3 AChR subunits, they exhibit significant differences in their functional properties. As discussed above, in addition to differences in expression levels and coexpression with ␤2 and ␤4 subunits, ␣6␤4 AChRs exhibit significantly different phar- (Table 1) (16, 18) . Therefore, both chicken ␣6 human ␤4 AChRs and rat ␣6 human ␤4 AChRs retain a unique agonist profile with nicotine, cytisine, and DMPP as poor partial agonists. In contrast, nicotine was shown to be a full agonist for chicken, rat, and human ␣3␤4 AChRs (Table 1) (16, 18, 19) . Nicotine behaves virtually as an antagonist on ␣6␤4 AChRs. The time course of the nicotine-induced current does not indicate either accelerated desensitization or channel block of the AChRs. Inhibition of ␣6␤4 AChRs by nicotine strongly resembles the action of nicotine previously described for chicken ␣3␤2 AChRs but not for ␣3␤4 AChRs (18) . After extensive studies of this phenomenon, these authors concluded that nicotine behaves as a competitive antagonist at low concentrations, but as a partial agonist at higher concentrations, and that its inhibitory action is at least in part contributed by the ␤2 subunit. Nicotine also behaves as an antagonist for rat homomeric ␣9 AChRs (20) . Epibatidine exhibits extremely high potency for ␣6␤4 AChRs. High potency of this alkaloid also was described recently for all recombinant and native, chicken, and human ␣3-containing AChRs (16) . Therefore, sensitivity to ACh and epibatidine is similar for ␣3␤4 AChRs and ␣6␤4 AChRs, whereas actions of cytisine, DMPP, and especially nicotine clearly distinguish between these two subtypes of AChR. These features could be extremely useful for potential future functional identification of native ␣6-containing AChRs.
Depletion of Ca 2ϩ ions from the extracellular solution resulted in a dramatic decrease of ␣6␤4 AChR-mediated currents. Similar phenomena were characterized originally for oocyte-expressed and native rat ␣3 AChRs (21, 22) . It was concluded that physiological concentrations of extracellular Ca 2ϩ ions enhance neuronal AChR-mediated currents by direct binding on the extracellular side of these AChRs. Alternatively, decrease of the ␣6␤4 AChR-mediated currents in low Ca 2ϩ could be the result of the prevention of activation of a secondary endogenous Ca 2ϩ -dependent Cl Ϫ current. This current is known to accompany currents mediated by recombinant AChRs or N-methyl-D-aspartate receptors with rela- tively high Ca 2ϩ permeability expressed in X. laevis oocytes (11, 15, 22) . However, the time course of the currents mediated through the oocyte-expressed ␣6␤4 AChRs suggests that the contribution of the Ca 2ϩ -dependent Cl Ϫ current is minimal or nonexistent. A Ca 2ϩ -dependent Cl Ϫ current usually is observed as a peak current with a relatively fast inactivation at the beginning of the agonist application and sometimes is misinterpreted as a fast component of desensitization (15, 22, 23) .
Preliminary in situ hybridization studies of mRNA expression for the ␣6 AChR subunit revealed the pattern of distribution of this subunit in developing rat brain (8) . Message for the ␣6 subunit was localized within the medial habenula, locus ceruleus, ventral tegmental area, and substantia nigra compacta. This restricted pattern distribution of ␣6 message in brain contrasts with the more diverse and diffuse distribution of the ␣4 (see Refs. 1 and 2 for review) and ␣7 (24, 25) subunits and rather parallels the distribution of the ␣3 AChR subunit (1, 26) . Now that we have demonstrated that ␣6 can participate in functional AChRs in combination with ␤4, the significance of ␣6 localization in brain will have more effect on our understanding the central effects of ACh, nicotine, and nicotinic drugs. Message for the ␤4 subunit is colocalized in, but not limited to, the brain areas that contain ␣6 mRNA (27) . Message for ␣6 RNA is localized in parts of the brain traditionally believed to participate in the rewarding properties of drugs of abuse, with one of the putative mechanisms of addiction involving dopamine release in the neurons of these areas (28) . Functional, unidentified, neuronal AChRs were shown to be present in these areas (29 -31). The substantia (32, 33) , and smoking seems to be protective in this disease (34) ; therefore, AChR subtypes with a limited distribution, including this nucleus, might be useful drug targets for subtypespecific AChR agonists intended for therapy of Parkinson's disease. With our initial demonstration that ␣6 can function as part of AChRs formed from subunit cDNAs expressed in X. laevis oocytes, ␣6 leaves the ranks of orphan subunits and joins the company of numerous potential AChR subtypes that are much better characterized as expressed cDNAs in oocytes than they are in any native neurons. Now the challenge is to detect ␣6 AChR proteins in neurons, determine their subunit composition, and relate their functional properties to those we have observed in oocytes. 
